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Several new therapeutic strategies are now considered for acute myeloid leukemia (AML) patients unfit for intensive
chemotherapy, including modulation of protein lysine acetylation through inhibition of histone deacetylases
(HDACs). These enzymes alter the acetylation of several proteins, including histones and transcription factors, as
well as several other proteins directly involved in the regulation of cell proliferation, differentiation and apoptosis.
Valproic acid (VPA) is a HDAC inhibitor that has been investigated in several clinical AML studies, usually in
combination with all-trans retinoic acid (ATRA) for treatment of patients unfit for intensive chemotherapy, for
example older patients, and many of these patients have relapsed or primary resistant leukemia. The toxicity of VPA
in these patients is low and complete hematological remission lasting for several months has been reported for a
few patients (<5% of included patients), but increased peripheral blood platelet counts are seen for 30 to 40% of
patients and may last for up to 1 to 2 years. We review the biological effects of VPA on human AML cells, the
results from clinical studies of VPA in the treatment of AML and the evidence for combining VPA with new
targeted therapy. However, it should be emphasized that VPA has not been investigated in randomized clinical
studies. Despite this lack of randomized studies, we conclude that disease-stabilizing treatment including VPA
should be considered especially in unfit patients, because the possibility of improving normal blood values has
been documented in several studies and the risk of clinically relevant toxicity is minimal.
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Acute myeloid leukemia (AML) is caused by clonal ex-
pansion of myeloblasts that have lost the normal regula-
tion of differentiation and proliferation; this causes bone
marrow accumulation of the leukemic cells, and thereby
general bone marrow failure, and eventually leukemization
and organ infiltration [1]. The median age at the time of
diagnosis is 65 to 70 years. Although the prognosis of AML
has improved during the last decade, this is mainly true
for younger adults who can receive the most intensive* Correspondence: hanne.fredly@med.uib.no
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reproduction in any medium, provided the ortreatment, including stem cell transplantation, whereas
the overall survival (OS) for older AML patients re-
mains poor [2].
The conventional intensive chemotherapy for AML usu-
ally has a treatment-related mortality of approximately 5%
[3]. The early mortality for patients receiving allogeneic
stem cell transplantation is approximately 20 to 25%, even
for patients without severe comorbidity [4]. Thus, a large
group of patients will be unfit for the most intensive thera-
peutic strategies due to age [5,6], severe non-hematological
diseases, reflected in their comorbidity score [7], or poor
performance status [6,8]. Another group of older pa-
tients should not receive intensive chemotherapy with the
intention of remission induction because they have high-risktd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Fredly et al. Clinical Epigenetics 2013, 5:12 Page 2 of 13
http://www.clinicalepigeneticsjournal.com/content/5/1/12disease and remission is unlikely [6,7,9]. In these patients,
less intensive treatment based on histone deacetylase
(HDAC) inhibition may be an alternative, either alone
or in combination with other low-toxic strategies [10].
Valproic acid (VPA) in combination with all-trans retinoic
acid (ATRA)
Biological and clinical effects of VPA
Valproic acid (VPA) is a short-chain fatty acid that is an
established antiepileptic agent, with proven activity also
in bipolar disorder, migraine and neuropathic pain [11].
It is generally well tolerated, but use of VPA in early
pregnancy is associated with an increased risk of congenital
malformations, including spina bifida in 1 to 2% of cases,
and the malformations seem to be related to the drug’s
anti-tumor properties [12].
VPA functions as a powerful HDAC inhibitor [13].
Acetylation is one of the main histone modifications
leading to the opening of chromatin and promoting
gene transcription, whereas histone deacetylation promotes
chromatin condensation and represses gene transcription
[14]. HDACs are overexpressed in malignant tissue, includ-
ing leukemic blasts [15]. HDAC inhibitors may therefore
result in re-expression of silenced tumor suppressor
genes in cancer cells, and potentially lead to cellular
differentiation and apoptosis [14].
VPA has a wide range of effects on AML cells and the
results from previous studies are summarized in Table 1
[16-38]. These observations clearly demonstrate that
VPA can induce differentiation, and has antiproliferative
and proapoptotic effects in AML cells. However, patients
are most likely heterogeneous with regard to both sus-
ceptibility to VPA and molecular mechanisms mediating
the antileukemic effects. Direct effects on the leukemic
cells seem most important, but indirect effects mediated
through increased antileukemic immune reactivity may
also contribute. Few studies have explored VPA as
monotherapy in AML [39,40] and only low response
rates have been seen (3 to 5%).
Biological and clinical effects of ATRA combined with VPA
In 1981, all-trans retinoid acid (ATRA) was proven
to differentiate human acute promyelocytic leukemia
(APL) cells in vitro [41], and ATRA has now changed
APL from a highly fatal to a highly curable disease
[42-44]. In APL, the absence of ATRA leads to HDAC
activities, inducing chromatin condensation and tran-
scriptional repression [45]. Pharmacological levels of
ATRA then induce a conformational change in the
promyelocytic leukemia (PML)/retinoic acid receptor
α (RARα) fusion oncoprotein, thereby allowing the re-
lease of HDAC complexes and recruitment of tran-
scriptional co-activators with growth suppression and
differentiation induction [46].Several clinical studies have investigated the combination
of ATRA and VPA in non-APL variants of AML. This com-
bination has antileukemic activity in experimental in vitro
studies [46] and is usually well tolerated by patients.
The results of these clinical studies are summarized in
Table 2 [19,39,40,47-51]. Based on these results, the
following conclusions can be made: 1) the combination
of VPA and ATRA has clinically relevant antileukemic
activity; 2) the combination is well tolerated, and the most
common side effects are dose-dependent and reversible
fatigue, and gastrointestinal toxicity; 3) the antileukemic
activity can be seen at serum levels below the generally ac-
cepted therapeutic levels used for antiepileptic treatment;
4) the treatment is also safe for older patients and can be
combined with low-toxicity chemotherapy; 5) a clinical
effect is only observed for a minority of patients, and in
several studies this is only observed in 20 to 40% of the
included patients; and 6) the most common effect on per-
ipheral blood cells is increased platelet counts, whereas
complete hematological remission is very uncommon.
ATRA therapy has dramatically improved the prognosis
of APL [42] and has also been used in the treatment of
non-APL AML [39,40,48,51]. ATRA toxicity, as reported
during treatment of APL, includes the ATRA or APL differ-
entiation syndrome [55]. This syndrome has an incidence
of 2 to 27% and a mortality rate of 2 to 15% [55,56]. Other
frequent side effects include dryness of mucosa, headache,
and increased transaminases and triglycerides [55]. Serious
side effects of ATRA 45 mg/m2/d are very uncommon
when VPA plus ATRA are used in the treatment of
non-APL AML (Table 2) [47].
VPA in combination with demethylating agents
The clinical experience of demethylating agents as
monotherapy in human acute myeloid leukemia (AML)
The nucleoside analogues decitabine and 5-azacitidine
(5-AZA) are the two demethylating agents most extensively
studied. Decitabine inhibits DNA methyltransferase (DNA
MTase) and causes DNA hypomethylation. It has shown
convincing activity in myelodysplastic syndrome (MDS) in
a large, phase III European trial, including 233 patients aged
60 years or older [57]; 13% of patients receiving decitabine
achieved complete remission (CR) and 6% achieved partial
remission (PR), compared with none in the best supportive
care group. In AML, a phase II multicentre study, including
55 patients older than 60 years, 25% of patients achieved
CR and 29% of patients had stable disease [58].
5-AZA is a ribose structure, which needs to be metabo-
lized by ribonucleotide reductase to be incorporated into
DNA; it cannot be combined with hydroxyurea due to
pharmacodynamic interactions [59]. 5-AZA has been ap-
proved for the treatment of MDS and has demonstrated
increased survival, compared to conventional treatment in
a randomized phase III study, including 358 patients [60].
Table 1 Functional or molecular targeting effects of valproic acid (VPA) on acute myeloid leukemia (AML) cells
Intracellular signaling and trafficking
Expression of the CXCR-4 receptor is decreased in CD34- AML cells, whereas increased expression is observed in CD34+ leukemic cells [25]. In vivo
treatment with VPA in combination with ATRA alters the phosphorylation status and the phosphoresponsiveness of several intracellular signaling
pathways, but the effects differ between patients [35]. VPA increases p21 but downregulates c-Myc expression at a transcriptional level [18].
Modulation of CBP activity and interaction with PML nuclear bodies may contribute to the effects of VPA [38]. The nucleolar morphology and
function is altered [36]. VPA also alters the overall expression pattern of the various HDACs [16].
AML cell proliferation, differentiation and apoptosis
VPA has an antiproliferative effect that is dose-dependent. The effects differ between patients and at lower concentrations even enhancement of
proliferation is seen for a subset of patients [37]. VPA reprograms the differentiation program in AML cells, especially in cells with a
myelomonocytic phenotype [19]. Animal studies of APL suggest that terminal granulocytic differentiation can also be seen [30]. Differentiation is
especially seen in t(8;21) AML cells [31].
Effects on leukemic stem cells
In animal models of APL, VPA causes rapid disease regression in induction of granulocytic differentiation, but discontinuation is associated with
immediate disease relapse, suggesting that leukemia-initiating cell activity is not affected by VPA [30]. Studies in human cells also suggest that VPA
spare or increase immature AML cells during in vitro culture [17]. Direct associations between epigenetic modifications and reprogramming of
normal as well as cancer stem cells are now emerging for other malignancies [33].
Effects on t(8;21) AML
In contrast to other AML subsets, VPA inhibits not only the mature AML cells but also the immature progenitors in AML1/ETO [17]. The drug
targets the AML1/ETO-HDAC complex, and thereby alters gene expression and induces differentiation [31]. VPA has specific effects in this AML
subset. The drug induces differentiation followed by apoptosis and accompanied by increased expression of repressed AML1 target genes [31].
Effects on antileukemic immune reactivity
In combination with 5-AZA, VPA causes induction of specific T cell responses against cancer-associated antigens [24]. The drug also increases the
susceptibility to NK cell-mediated lysis through upregulation of NK cell ligands on the leukemic cells [32,34]; the NK cells then target leukemic
stem cells [29]. This effect is also seen for ATRA [34]. AML cells are also sensitized to TRAIL/Apo2L-induced apoptosis by VPA [27]. Spontaneous
in vitro apoptosis is associated with immunogenic apoptosis with HSP release and calreticulin exposure; VPA does not interfere with this
expression during stress-induced apoptosis [20].
Chemosensitivity and chemoresistance
A recent experimental study suggested that VPA induces a broad chemoresistance phenotype in AML cells [26]. However, clinical data does not
support this observation since VPA can be combined with cytarabine, hydroxyurea and 6-mercaptopurin in the treatment of AML patients [22,23].
One marker of sensitivity may be UTX (KDM6A), which has a functional relationship between protein acetylation and lysine-specific methylation
[21]. Resistance programs have also been identified that compensate for the HDAC inhibitor-induced global hyperacetylation, and these programs
include MAPKAPK2, HSP90AA1, HSP90AB1 and ACTB [21]. One study also suggested serum HSP90 as a possible marker of sensitivity to VPA [22].
Cellular high expression of FOSB may be another sensitivity marker [28].
5-AZA, 5-azacytidine; AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid; CXCR-4, C-X-C chemokine receptor type 4;
FOSB, FBJ murine osteosarcoma viral oncogene homolog B; HDAC, histone deacetylase; HSP, heat shock protein; HSP90, heat shock protein 90; HSP90AA1, heat
shock protein 90 kDa alpha (cytosolic), class A member 1; HSP90AB1, heat shock protein 90 kDa alpha (cytosolic), class B member 1; MAPKAPK2, mitogen-activated
protein kinase-activated protein kinase 2; NK, natural killer; PML, promyelocytic leukemia; UTX, ubiquitously transcribed tetratricopeptide repeat, X chromosome; VPA,
valproic acid.
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years 50.8% of patients in the treatment group were alive
versus 26.2% in the conventional treatment group.
Similarly, the same clinical study showed a superior 2-year
survival rate for the subgroup of patients with bone marrow
blast counts between 20 to 30% (that is, patients with AML
according to current World Health Organization (WHO)
criteria), with 2-year survival rates of 50 and 16% in the
treatment and conventional group, respectively, and fewer
days in hospital for the 5-AZA treatment group [61]. Based
on its documented safety and efficiency, 5-AZA is an
acceptable alternative for treatment of AML, at least in
selected subsets of older patients.
Biological and clinical effects of combining VPA and
demethylating agents
The epigenetic changes in AML include altered DNA
methylation and histone acetylation leading to genesilencing. Several clinical studies have investigated the
effect of combining VPA with DNA demethylating agents
[62]. The results from five different studies are summarized
in Table 3 [63-67]. Additional biological studies of these
patients demonstrated that DNA hypomethylation and
histone H3/H4 acetylation can be induced by this treatment
[66]. Taken together, these studies suggest that the toxicity
of this regimen is acceptable even in older patients; enceph-
alopathy/confusion has been described in a relatively high
number of patients in certain studies, but this would be
an expected dose-dependent effect of VPA. The studies
of VPA plus ATRA in older patients suggests that it may
be difficult to reach the ordinary therapeutic serum
levels of VPA in these patients; however, relatively low
serum levels may be sufficient for induction of an antileu-
kemic response [51]. Taken together, these studies suggest
that VPA plus a demethylating agent is more effective
than combining VPA and ATRA. The results summarized
Table 2 Valproic acid (VPA) and all-trans retinoic acid (ATRA) in the treatment of acute myeloid leukemia (AML): summary of clinical studies
Study Number
of patients
Median age
(range) (years)
Diagnosis Treatment Results Common toxicity
Ryningen et al.,
2009 [51]
24 71 (47 to 86) AML ATRA 22.5 mg/m2 × 2 day 1 to 15. VPA and
theophylline iv day 3 to 7, thereafter, orally
indefinitely. Serum levels of theophylline 50
to 100 μM, VPA 200 to 700 μM.
MDS criteria: 9/22 patients had increasing
cell counts and 4/22 patients (18%) HI [52,53].
Median survival 64 days (7 to 644 days).
Two patients had atrial fibrillation.
Fatigue and nausea were most common.
Bellos et al., 2008 [47] 22 71.5 (41 to 89) AML (95%)
or MDS
VPA 150 to 300 mg/d. ATRA 45 mg/m2/d
for 14 days.
MDS criteria: four patients HI-P and one
patient HI-E. Treatment duration 37 days
(4 to 730 days).
Usually well tolerated. Two patients had
ATRA syndrome and two patients had
continuous fever.
Cimino et al.,
2006 [19]
8 61.5 (31 to 69) AML (88%) or
CML blast crisis
VPA 15 to 30 mg/kg/d with serum levels
50 to 110 μg/ml. ATRA 45 mg/m2 from day
14. Cytoreductive drugs if hyperleukocytosis.
Two patients (25%) HI and five patients had
stable disease. No clinical response according
to AML criteria [54]. Survival 119 days
(60 to 184 days).
One patient had grade III hepatic toxicity,
and one patient had vertigo and tremor.
Kuendgen et al.,
2006 [40]
58 71 (42 to 86) AML VPA reaching serum levels 50 to 100 μg/ml.
ATRA either 80 mg/m2 days 1 to 7 every
second week, or ATRA 15 mg/m2/d from
day 4. Total of 31 patients received VPA
monotherapy. Cytoreductive drugs if
hyperleukocytosis.
AML criteria: one patient CR, one patient CRi
and one patient PR;5% response. MDS criteria:
16% responses, 34% stable disease and 50%
progressive disease. No difference between
treatment groups. Median OS 6.74 months.
Seven patients had tremors. Four patients
had grade I/II skin toxicity, three patients
had grade I/II gastrointestinal toxicity and
one patient had pleural effusion.
Bug et al., 2005 [48] 26 69 (59 to 84) AML (92%) or
advanced MDS
VPA 5 to 10 mg/kg/d, escalating doses to 5
to 64 mg/kg. ATRA 45 mg/m2/d.
Cytoreductive drugs if hyperleukocytosis.
One patient PR, one patient had minor
response (2/19) and no patients CR; 10%
responses. Survival not reported.
Three patients had grade IV neurological
or pulmonary toxicity and there were 21
events with grade III toxicity.
Raffoux et al.,
2005 [50]
11 82 (70 to 85) AML VPA reaching serum levels 50 to 100 μg/ml.
ATRA 45 mg/m2/d from day 7. Theophylline
reaching serum levels 10 to 15 μg/ml.
Cytoreductive drugs if hyperleukocytosis.
AML criteria: one patient CR and two patients
CRi. According to MDS criteria: two additional
patients with HI. Survival 6 months (1 to
28 months).
Main side effects were tremor, mental
confusion and theophylline-related
palpitations.
Kuendgen et al.,
2005 [39]
75 67 (21 to 84) AML (43%)
or MDS
VPA reaching serum concentrations 50 to
100 μg/ml. Total of 66 patients received
VPA monotherapy. ATRA 80 mg/m2 days 1
to 7 every second week.
MDS criteria: 18 patients responded (24%),
one patient CR, one patient PR, 16 patients
HI and 25 patients had stable disease.
Median response duration 4 months
(2 to 27 months).
Skin and gastrointestinal toxicity.
Pilatrino et al.,
2005 [49]
20 70 (63 to 80) AML (65%)
or MDS
VPA 10 mg/kg/d escalating to 311 to
693 μM. ATRA 45 mg/m2/d. Cytoreductive
drugs if hyperleukocytosis.
MDS criteria: 30% patients HI and no
patients CR. Median duration of response
189 days (63 to 550 days).
Neurologic toxicity and bone pain.
AML, acute myeloid leukemia; ATRA, all-trans retinoic acid; CML, chronic myeloid leukemia; CR, complete remission; CRi, complete remission incomplete (peripheral blood criteria not fulfilled); HI, hematological
improvement; HI-E, hematological improvement in erythrocytes; HI-P, hematological improvement in platelet counts; MDS, myelodysplastic syndrome; OS, overall survival; PR, partial remission; VPA valproic acid.
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Table 3 Combination of histone deacetylase (HDAC) inhibition and demethylating agents: summary of clinical studies
Study Number of
patients
Median
age (years)
Diagnosis Treatment Results Common toxicity
Raffoux et al., 2010 [64] 65 72 AML (85%) or
high-risk MDS
5-AZA 75 mg/m2. VPA 35 to 50 mg/kg
po day 1 to 7. ATRA 45 mg/m2 po day
8 to 28. Six cycles.
After six cycles, 34 patients survived:
13 patients (38%) CR, two patients (6%)
PR and 14 patients (41%) had stable
disease. Median OS was 12.4 months.
Confusion 33 events, infection
76 events.
Blum et al., 2007 [63] 25 70 AML Decitabine 15 to 20 mg/m2/d iv days 1
to 10 every 28 days. VPA 15 to 20 mg/kg
days 5 to 21 in ten patients.
Response rate was 44%: four patients
CR, four patients CRi and three patients
PR (AML criteria). Survival not reported.
Neutropenic fever (64%), fatigue
and infection (both 48%) were
most common.
Soriano et al., 2007 [65] 53 69 AML (92%) or
high-risk MDS
5-AZA 75 mg/m2/d. VPA 50 to 75 mg/kg/d
days 1 to 7. ATRA 45 mg/m2 days 3 to 5.
Treatment repeated every 3 weeks.
Overall response rate was 42%: 12
patients (22%) CR. Survival not reported.
Two events of grade IV and 11
events of grade III
non-hematological toxicity;
mainly fatigue or other
neurotoxicities.
Garcia-Manero et al., 2006 [66] 54 60 AML (89%)
or MDS
Decitabine 15 mg/m2/d iv. VPA 20 to
50 mg/kg days 1 to 10. Treatment
repeated every fourth week.
Twelve patients (22%) had responses:
10 patients CR and two patients CRp.
OS 6 months (0.6 to 20.2 months).
Fatigue, nausea and diarrhoea
were the most common
non-hematological toxicities.
Maslak et al., 2006 [67] 10 66.5 AML (80%)
or MDS
5-AZA 75 mg/m2/d days 1 to 7. Sodium
phenylbutyrate 200 mg/kg/d iv days 8
to 12. Treatment repeated every 21 to
28 days.
Three patients (30%) PR and two
patients (20%) had stable disease.
Duration of response was 45 days
(37 to 136 days). Survival not reported.
Three patients had neutropenic
fever. Nausea, dizziness and
fatigue were common.
5-AZA, 5-azacytidine; AML, acute myeloid leukemia; ATRA, all-trans retinoic acid; CR, complete remission; CRi, complete remission incomplete (peripheral blood criteria not fulfilled); CRp, incomplete platelet recovery;
MDS, myelodysplastic syndrome; OS, overall survival; PR, partial remission; VPA, valproic acid.
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are generally better for patients treated with VPA plus
demethylating agent. However, with the lack of randomized
clinical studies it is not possible to make a firm conclusion
about the preferred regimen combination.
VPA versus other histone deacetylase (HDAC) inhibitors in
the treatment of human AML
Except for VPA, several other HDAC inhibitors have been
developed, as described in a recent review article [14], and
used in clinical studies [68,69]. In 2007, vorinostat was the
first HDAC inhibitor to be approved as treatment for
the malignant disease primary cutaneous T cell lymphoma.
Phase I and phase II studies in AML have been undertaken
combining vorinostat with demethylating agents or chemo-
therapy. The response rates have varied between 4 to 86%
with combined treatment showing the best results [70-74].
Mocetinostat (MGCD0103) has shown response rates
from 10 to 30% with best results when combined with
5-AZA [14]. Entinostat was also combined with 5-AZA
and showed a response rate of 44% in 31 patients, in-
cluding 7.5% CR, whereas a monotherapy phase I trial
showed no responses [14]. Panobinostat (LBH-589) and
romidepsin have also been developed, and they showed no
response in phase I trials as monotherapy for different
types of leukemia and MDS in 15 and 20 patients, respect-
ively [14]. Other HDAC inhibitors have been developed
but data are still preliminary. As for VPA, it is essential to
also combine these HDAC inhibitors with other active
substances to increase the response rates. Finally, butyrate
is still considered as a therapeutic tool in clinical oncology
[75], but, as previously reviewed, the results from available
clinical studies in hematological malignancies are not
promising [76,77].
To conclude, VPA is still the best investigated HDAC
inhibitor for the treatment of human AML, both with
regard to low-toxicity disease-stabilizing treatment and
more intensive remission-inducing treatment.
Low-toxicity treatment with cytotoxic drugs: an alternative
to VPA or a possibility of combination therapy?
Several clinical reports have described the combined use
of VPA with low-toxicity conventional chemotherapy. As
described below, VPA has been combined with cytarabine,
hydroxyurea and 6-mercaptopurine (6-MP); three drugs
that interact with nucleic acid synthesis through targeting
of different intracellular molecules.
Low-dose cytarabine
Cytarabine is an analogue of deoxycytidine and shares
the same metabolic pathway as this deoxycytidine [78].
Cytarabine is metabolized to its active triphosphate
form, which inhibits the enzyme DNA polymerase alpha
and is incorporated into elongating DNA strands, therebycausing chain termination. However, this triphosphate form
is degraded by several enzymes and this intracellular
metabolism is also regulated by several feedback mecha-
nisms. The cytarabine-mediated cytotoxicity caused by its
active triphosphate form is thereby determined by a com-
plex interplay between cytarabine dose, anabolism, catab-
olism, and endogenous purine and pyrimidine levels [78].
Cytarabine is a cornerstone of AML treatment [79]. In
1987, treatment with low-dose subcutaneous cytarabine
in 129 AML patients resulted in a CR rate of 31% and
PR rate of 18% [80]. Later, low-dose cytarabine was
combined with various therapeutic agents, including
other cytotoxic drugs, growth factors, arsenic trioxide
and homoharringtonine [81-84]. In these four trials, the
CR rates were 14 to 52% and the cytarabine dose varied
between 15 to 20 mg/m2/d for 10 to 14 days. Although
low-dose cytarabine is frequently used, the mechanism of
action is not known in detail and may include differenti-
ation induction, as well as direct cytotoxic effects [85].
The biological effects and clinical results of low-dose
cytarabine have been recently reviewed [85]. The following
conclusions can be made based on the currently available
clinical studies in human AML: 1) the treatment has
an antileukemic effect and can improve survival; 2) the
treatment is most effective for patients with low- and
intermediate-risk disease, and the improved survival is
mainly due to a beneficial effect in a minority of patients
achieving complete hematological remission; 3) survival is
not improved for patients with high-risk cytogenetic ab-
normalities; 4) the cytarabine dose used in these studies
varies between 10 and 40 mg/m2 given once or twice daily,
and the duration of treatment is usually 10 days but up to
21 days has been used; 5) treatment-related mortality is
seen at least when using the higher doses, but this mortality
shows a wide variation between studies; and 6) combination
with other cytotoxic drugs is possible, but this has been
investigated mainly in very small clinical studies and some
of these studies suggest that the treatment-related mortality
will then be increased.
Although effective, a major drawback of subcutaneous
cytarabine is that patients often have to attend the out-
patient department to receive the subcutaneous injections.
Hydroxyurea
DNA synthesis requires production of deoxyribonucleotides
and ribonucleotide reductase is necessary for this pro-
duction [86]. Hydroxyurea inactivates the enzyme directly
through electron donation but also indirectly through
conversion to nitric oxide. This enzyme is also necessary
for DNA repair and causes a block at the G1/S transition
of the cell cycle, and thereby has cytotoxic effects.
Hydroxyurea has been used for decades in the treatment
of hematologic malignancies; its activity is based on inhib-
ition of the ribonucleotide reductase enzyme, and thereby
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supporting clinical data, hydroxyurea is often used in
AML for older patients not eligible for intensive
chemotherapy. In a retrospective analysis of 244 older
patients, 52% of patients received hydroxyurea and no
significant difference in survival compared to treatment
with 6-thioguanine (6-TG) or low-dose cytarabine was
found [88]. A recent randomized clinical trial showed that
low-dose cytarabine was superior to hydroxyurea in 217
older patients [89], resulting in CR rates of 18% versus 1%,
respectively. In this study, the cytarabine dose was stan-
dardized to 20 mg/m2 twice daily for 10 days every 4 to 6
weeks, whereas hydroxyurea was administered to keep the
white blood cell count below 10 x 109/l. The addition of
ATRA made no significant difference. Another small
study showed acceptable safety and a CR rate of 41.6% for
high-dose hydroxyurea (100 mg/kg/d) administered daily
until bone marrow aplasia, or for a maximum of 30 days
for 12 patients with poor-risk AML [90].
6-mercaptopurine (6-MP)
6-MP is a thiopurine and an analog of hypoxanthine
[91,92]. The mechanism for its cytotoxic activity seems
to be intracellular conversion to 6-TG nucleotides and
methylated derivatives, which have a cytotoxic effect.
Several molecular mechanisms may contribute to this
effect, including incorporation of 6-TG nucleotides into
nucleic acids. The drug has been used in AML therapy,
mainly in palliative or maintenance treatment [93,94]. In
Japanese trials, the drug was used at the dose of 70 mg/m2
for 7 days in repetitive cycles. A major advantage of both
hydroxyurea and 6-MP is the oral administration, which
makes management of outpatients easier.
The possibility to combine VPA with low-toxicity
cytotoxic therapy
Clinical studies have shown that VPA, possibly together
with ATRA, can be combined with low-dose cytarabine
[20,95,96], hydroxyurea and 6-MP [23,95]. The results from
the first three studies of VPA plus low-dose cytarabine
are conflicting. One study concluded that the combin-
ation had limited clinical effect [96], while induction of
CR was seen in the two other studies [20,95]. The lar-
gest study included 36 patients treated with continu-
ous administration of VPA, intermittent oral ATRA
(21.5 mg/m2 for 14 days every third month) and sub-
cutaneous cytarabine (10 mg/m2 once daily for 10 days
every third month) [95]. If cytarabine could not control
hyperleukocytosis, it was replaced by hydroxyurea or
6-MP to maintain the peripheral blood blast count
below 50 x 109/l and to avoid symptoms of leukostasis
[97]. In this study, the median age of the patients was
77 years (range 48 to 90 years), 11 patients responded
to the treatment according to the MDS response criteriaand two of these patients achieved complete hematological
remission. The responders had a median survival of 171
days (range 102 to >574 days) and most of this time was
spent outside hospital. These results suggest that a sub-
set of patients will benefit from this treatment, and this
is supported by a third study [20].
Experimental studies suggest that VPA may also be
combined with other therapeutic agents in the treatment
of human AML [98-109]. These results are summarized
in Table 4.
Best supportive care versus disease-stabilizing treatment
based on VPA in unfit AML patients: should VPA be
recommended even though randomized clinical trials are
not available?
Best supportive care in AML generally refers to treatment
with antibiotics and transfusions of blood products.
Low-intensity therapy is often offered to control
leukocytosis [110]. Retrospective analyses of a group of
244 AML patients not fit for standard treatment, but
with 72.5% of patients receiving hydroxyurea, low-dose
cytarabine or 6-TG, showed a median OS of 178 days
(range 1 to 3,278) [88]. Eighty per cent of patients survived
less than 12 months. Another retrospective study, including
2,657 AML patients older than 65 years, showed that
86% of patients died within 1 year [111]. Median OS
was 2 months, ranging from 1 month for patients aged
85 years and older, to 3 months for patients aged 65 to
74 years. In this last study, 30% of patients received
low-toxicity chemotherapy and the average age of
these patients was 73 years, whereas the average age
of the whole group was 77 years. Median OS for
treated patients was 6 months longer than for the un-
treated patients, regardless of age at the time of diag-
nosis [111]. Similarly, a systematic review of clinical
studies published between 1989 and 2006, including a
total of 12,370 AML patients with median age 70 years,
showed a median OS for patients receiving best sup-
portive care of only 7.5 weeks [112]. Approximately 50%
of these patients received intensive induction therapy,
30% received non-intensive chemotherapy and 20%
received best supportive care.
These studies clearly demonstrate that unfit AML
patients only receiving supportive care usually have a
very short survival. Disease-stabilizing treatment based
on VPA offers an opportunity of improved peripheral
blood cell counts, to such a degree that the risk of bleed-
ing or infections and the need for erythrocyte transfusions
is reduced, compared with the pre-therapy situation. Is it
then justified to recommend VPA-based treatment to
these patients in the absence of randomized clinical
studies, or should they still receive only supportive
treatment? In our opinion, the answer is that VPA-
based treatment should be recommended, because: 1)
Table 4 Possible combinations of valproic acid (VPA) with other therapeutic agents: current experimental evidence
Agent Evidence Study
Curcumin Curcumin is a natural anticancer agent that affects the expression of NF-κB,
Bcl-2 and Bax in leukemic cells. The combination with VPA causes upregulation
of Bax with proliferation arrest, sub-G1 DNA accumulation and cell death in
the HL-60 AML cell line. The effect is dependent on p38 activation.
Chen et al., 2010 [100]
Folate receptor beta The folate receptor beta mediates antiproliferative effects in AML cells and
VPA upregulates the expression of this receptor. VPA and ATRA, combined
with targeting of this receptor, may therefore have additive or synergistic
antileukemic effects.
Qi and Ratnam, 2006 [105]
HSP90 inhibition Co-treatment of the AML1/ETO-expressing Kasumi-1 cell line with VPA and
the HSP90 inhibitor 17-AAG causes a synergistic inhibition of downstream
signaling of mutated c-KIT.
Yu et al., 2011 [108]
Hydralazine Hydralazine is a nontoxic agent with DNA MTase-inhibiting effects. A clinical
study suggested that the combination of hydralazine and VPA was a nontoxic
treatment with an antileukemic effect in vivo. The effect has not been
compared with VPA in combination with decitabine or 5-AZA.
Candelaria et al., 2011 [99]
mTOR inhibition Studies in AML cell lines show no additive proapoptotic effects, but only a
limited number of cell lines were examined. However, in other experimental
models of Flt3-ITD-transformed cells, VPA and mTOR inhibitors had synergistic
proapoptotic effects.
Cai et al., 2006 [98]; Ryningen
et al., 2012 [106]
NF-κB inhibition Experimental studies suggest that the antileukemic effect of DNA MTase and
HDAC inhibition is not only caused by epigenetic mechanisms, but also by
additional and independent inhibition of NF-κB. Specific NF-κB inhibitors are
now being developed and the antileukemic effects of proteasome inhibitors
are also most likely caused by NF-κB inhibition.
Fabre et al., 2008 [101]
p53 agonism, nutlin The p53 agonist nutlin was combined with VPA, and the two drugs caused a
synergistic induction of p53-dependent apoptosis in AML cell lines and
primary AML cells. This synergism was also demonstrated in xenograft models
of human AML.
McCormack et al., 2012 [103]
Proteasome inhibitors,
including bortezomib
This combination has an antiproliferative effect with cell cycle arrest of AML
cell lines. Apoptosis is induced through caspase activation, and inhibition of
cyclin D and telomerase is induced. The two drugs have synergistic effects.
This synergism is also seen for other proteasome inhibitors, and, at least in
certain experiments, the antileukemic effect is stronger for the proteasome
inhibitors NPI-0051 and PR-171 than for bortezomib.
Fuchs et al., 2009 [102]; Nie et al.,
2012 [104]; Wang et al., 2011 [107]
sTRAIL When VPA was combined with an anti-CD33 single chain fragment linked
to sTRAIL, the two agents had synergistic effects on apoptosis induction in
primary human AML cells.
ten Cate et al., 2009 [109]
17-AAG, 17-N-allylamino-17-demethoxygeldanamycin; 5-AZA, 5-azacytidine; AML, acute myeloid leukemia; ATRA, all-trans retinoic acid; Bax, Bcl-2-associated X
protein; Bcl-2, B-cell lymphoma 2; DNA MTase, DNA methyltransferase; HDAC, histone deacetylase; HSP90, heat shock protein 90; ITD, internal tandem
duplications; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; sTRAIL, soluble tumor necrosis
factor-related apoptosis-inducing ligand; VPA, valproic acid.
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reduce the risk of potentially severe complications; 2)
all available studies suggest that this advantage can be
achieved with acceptable toxicity; and 3) the low-toxicity
justifies that this treatment is used for a period of several
weeks even though the response rate is less than 50%.
Future perspectives: the development of VPA as an
antileukemic agent
Autologous antileukemic immune reactivity: experimental
artefact or clinical reality?
The strategy to use tumor-specific vaccines as an in-
dividualized treatment was suggested several decades
ago [113], and in vivo experiments in mice have supported
this strategy [114]. However, whether enhancement of
antileukemic immune reactivity is possible in humans(for example through vaccination with AML-associated
antigens) requires further study. The use of such an
approach as a low-toxicity strategy in older patients is
supported by several observations. First, primary human
AML cells can undergo immunogenic apoptosis with
exposure of calreticulin, and release heat shock protein
70 (HSP70) and heat shock protein 90 (HSP90); this
may initiate or enhance the development of antileukemic T
cell reactivity [115]. Second, a prognostic impact of serum
heat shock protein (HSP) levels has been suggested
[116-119], possibly caused by soluble HSPs that facilitate
immunogenic presentation of the client proteins. Finally,
our recent study demonstrated that AML patients are
heterogeneous with regard to systemic levels of immuno-
regulatory cytokines and patients could be subclassified
based on their serum cytokine profiles; the effect of
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subsets [22]. Thus, the possibility to enhance autologous
antileukemic immune reactivity should be studied further
as a low-toxicity treatment in human AML, and this
strategy should combine with antileukemic chemotherapy
[120]. Immunological side effects should be evaluated in
future clinical studies of VPA treatment in human AML.
What are the response criteria for studies of AML-stabilizing
therapy?
The MDS response criteria developed by the International
Working Group (IWG) for MDS [52,53] have been
used to describe the effects of AML patients receiving
disease-stabilizing treatment. The alternative IWG criteria
for response in AML [54] are developed for AML patients
treated with intensive chemotherapy, with the intention to
induce complete hematological remission. However, with a
palliative treatment strategy, minor hematological improve-
ment or disease stabilization are also important in AML.
Furthermore, the question of duration of the response is
important in the MDS criteria. Duration of the response is
certainly important for AML patients receiving disease-
stabilizing therapy, but the durations are generally expected
to be shorter in disease-stabilizing treatment of highly
aggressive AML than for MDS patients with a much
longer expected survival even without disease-directed
therapy. Responses of shorter duration would therefore be
of biological as well as clinical relevance in patients with
AML. Complete hematological remission of any duration is
important and may lead to longer survival even in patients
receiving low-intensive treatment [54]. However, the MDS
criteria are more detailed and provide the best opportunity
to describe minor responses more accurately.
In a previous study exploring the combination of VPA,
ATRA and theophylline in unfit AML patients, increased
normal peripheral blood cell counts were also described
for patients who did not fulfill the criteria for hematological
improvement, as defined by the MDS criteria [51]. In this
study, improvements of platelet levels, increased neutrophil
or reticulocyte counts, or transfusion independency of
durations shorter than 8 weeks, were reported. This is
an alternative way of describing minor responses during
palliative treatment in AML. Reporting of such small re-
sponses is justified because AML is usually a rapidly
progressive disease and any spontaneous improvement is
regarded as unexpected. However, the best solution would
be to gain a general agreement on specific response criteria
for patients receiving AML-stabilizing therapy.
How should quality of life (QoL) be evaluated in early
clinical trials?
Quality of life (QoL) is reduced in AML patients particu-
larly at the time of diagnosis, due to the symptoms and
signs of the disease, the information about the diagnosisand prognosis, and the initial treatment, but it usually
improves and stabilizes [121,122]. There is no differ-
ence in QoL in older AML patients receiving intensive
or non-intensive treatment when comparing the pre-
treatment basic values, and the values after diagnosis
and during treatment [123,124]. Different instruments
and questionnaires are used to quantitatively measure
QoL in AML, as well as in other hematologic malignancies,
but the European Organization for Research and Treatment
of Cancer (EORTC) QLQ-C30 questionnaire is one of the
most commonly used scientific tools [121-123]. Evaluation
of QoL is often not included in early phase II studies, but
is important in larger randomized trials. An alternative for
phase II studies is to report parameters, such as time in
hospital versus days at home, to describe the situation of
the patients, and such factors are most likely important
for the patients’ QoL. Since previous studies have shown
that QoL is related to response to therapy [125], it is likely
that treatment-induced disease stabilization or even remis-
sion induction due to low-intensity treatment would lead to
an improvement in QoL.
Review and conclusion
Epigenetic strategies in AML are regarded as promising.
The detection of reversible epigenetic changes reflected
in the chromatin structure has increased our understanding
of leukemia development and identified new therapeutic
targets [126-128]. In addition to clinical trials with HDAC
inhibitors, the number of trials with demethylating agents
is also increasing and the combination of these two epigen-
etic strategies seem to have synergistic effects [129,130]
(Table 3). HDAC inhibitor monotherapy has limited effects
in AML and this treatment should be combined with other
antileukemic agents in future clinical studies [39,40].
Particularly in the treatment of older AML patients,
new targeted therapies should be tried and epigenetic
strategies then represent well tolerated alternatives.
Further increase of response rates can hopefully be made
through development of low-toxicity combination therapy.
Thus, in future, HDAC inhibitors should form part of the
AML treatment, at least for older patients or patients unfit
for intensive chemotherapy. A future role of VPA in the
treatment of myeloproliferative diseases, including AML,
is also supported by recent observations suggesting that
this agent may be useful in chronic myeloproliferative
neoplasms [131,132].
The available studies of VPA therapy in human AML
have demonstrated that HDAC inhibition is a therapeutic
strategy that should be investigated further. Future clinical
studies should address the question of whether VPA, or any
other drugs, should be the preferred HDAC inhibitor and
investigate the optimal drug(s) to combine with HDAC
inhibition. Randomized clinical trials are also needed to
compare HDAC inhibition with alternative therapeutic
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should be considered, particularly in patients unfit for
more intensive chemotherapy. This view is based on the
available results from several clinical studies, which shows
that VPA is the HDAC inhibitor most extensively investi-
gated in human AML, this treatment can induce a clinically
relevant improvement in peripheral blood cell counts and
stabilization of the clinical status for a subset of AML pa-
tients, and the risk of clinically relevant toxicity is minimal.
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